Hepcinat LP

Hepcinat LP is a fixed-dose combination tablet containing Ledipasvir and Sofosbuvir for oral administration. It is a prescription medicine that can be purchased by a patient only against a valid prescription of a healthcare professional. Do not share this hepatitis medicine with others because it can cause serious side effects to people until the condition is not monitored by a pharmacist.
 
Hepcinat LP (Ledipasvir/Sofosbuvir) is a very effective HCV drug that is used to treat chronic hepatitis C (an ongoing viral infection that damages the liver). This drug is used in a combination with another drug, to prevent the spread of HCV throughout the body.
 
Hepcinat LP is a direct-acting antiviral (DAA) medication. DAAs are a group of medications that directly block the ability of the hepatitis C virus to make copies of itself.
 
It is a combination of two direct-acting antiviral drugs that target different steps of the hepatitis C virus (HCV) life cycle. One is Sofosbuvir, which is a nucleotide polymerase inhibitor, and the other is Ledipasvir, which is an NS5A inhibitor. Sofosbuvir interferes with the reproduction of the virus�s genetic material, stopping the production of new Hep C virus. Ledipasvir works by interfering with a protein needed to complete the Hep C virus life cycle in the liver cell.